| Title |
New Strategies in the Management of Guillain–Barré Syndrome
|
|---|---|
| Published in |
Clinical Reviews in Allergy & Immunology, September 2013
|
| DOI | 10.1007/s12016-013-8388-5 |
| Pubmed ID | |
| Authors |
Jinting Xiao, Alain R. Simard, Fu-Dong Shi, Junwei Hao |
| Abstract |
Guillain-Barré syndrome (GBS) is an acute and usually monophasic, neurological, demyelinating disease. Although most patients have good outcomes without sequelae after conventional plasma exchange and intravenous immunoglobulin therapy, 20 % of patients continue to have severe disease and 5 % die of their disease. Therefore, there is an obvious need for more acceptable and efficacious therapies. Experimental autoimmune neuritis (EAN) is the classical animal model for GBS. As there is no specific drug for GBS, several drugs targeting the humoral and cellular components of the immune response have been used to treat EAN in the endeavour to find new treatment alternatives for GBS. This review focused on some new strategies for GBS, which have been reported but have not yet been widely used, and on the main drugs which have been investigated in EAN. |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 14% |
| Student > Bachelor | 6 | 14% |
| Other | 4 | 10% |
| Student > Postgraduate | 3 | 7% |
| Librarian | 2 | 5% |
| Other | 6 | 14% |
| Unknown | 15 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 31% |
| Nursing and Health Professions | 5 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Arts and Humanities | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 17 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2013.
All research outputs
#21,476,880
of 23,975,976 outputs
Outputs from Clinical Reviews in Allergy & Immunology
#638
of 690 outputs
Outputs of similar age
#183,033
of 207,022 outputs
Outputs of similar age from Clinical Reviews in Allergy & Immunology
#5
of 6 outputs
Altmetric has tracked 23,975,976 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 690 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,022 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.